Amicus Therapeutics (FOLD)

$14.25 +0.04 (0.28%)
Market Cap 4.38B
Revenue (ttm) 528.30M
Net Income (ttm) -56.11M
EPS (ttm) N/A
PE Ratio 355.25
Forward PE 118.42
Profit Margin -10.62%
Debt to Equity Ratio 1.70
Volume 5,937,300
Avg Vol 9,720,024
Day's Range N/A - N/A
Shares Out 308.53M
Stochastic %K 98%
Beta 0.46
Analysts Strong Sell
Price Target $14.75

Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 662 2000
Fax: 609 662 2001
Address:
47 Hulfish Street, Princeton, United States
JuggernautRaider
JuggernautRaider Dec. 23 at 12:59 PM
$TNXP I’ve been investing in Tonix for over a year and have noticed a lot of animus towards Seth “Leader Man”. He has done a nice job IMO since I have been invested, but he is getting up there in years. Does anyone else think he could be replaced soon like Durso did Garg at $ALT ? Any top choices? Not every CEO can be like the ones at $NUVB and $FOLD … unfortunately 😣
2 · Reply
Avocado_smash
Avocado_smash Dec. 22 at 10:35 PM
$ZIM last week $FOLD this week $ZIM 🚀🚀🚀
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 5:35 PM
$BMRN makes a bold $4.8B move — is this a rare-disease power play? 💰🧬 BioMarin agreed to acquire $FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to strengthen its portfolio. That’s immediate scale plus future optionality in one deal. Full deal breakdown and what it means for both stocks 👉 https://www.zacks.com/stock/news/2807526/biomarin-to-buy-rare-disease-drugmaker-amicus-therapeutics-for-48b?cid=sm-stocktwits-2-2807526-teaser-25832&ADID=SYND_STOCKTWITS_TWEET_2_2807526_TEASER_25832
0 · Reply
TeeMan123
TeeMan123 Dec. 22 at 5:24 PM
$FOLD well this was a long ride.. happy to see it come to fruition albeit the purchase price is much lighter than I would have expected. Signing from this board,, GL to you all going forward
0 · Reply
BullMaven
BullMaven Dec. 22 at 4:51 PM
$FOLD congrat to fold bag holders
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 4:35 PM
$BMRN makes a big move with $FOLD acquisition! 💥 BioMarin is acquiring Amicus Therapeutics for $4.8B, boosting its rare disease portfolio with Galafold and Pombiliti-Opfolda. This strategic deal, expected to close in Q2 2026, is expected to be accretive within the first 12 months post-closure. 📈 Discover how this deal could reshape BMRN's future here 👉 https://www.zacks.com/stock/news/2807526/biomarin-to-buy-rare-disease-drugmaker-amicus-therapeutics-for-48b?cid=sm-stocktwits-2-2807526-body-25834&ADID=SYND_STOCKTWITS_TWEET_2_2807526_BODY_25834
0 · Reply
biotech
biotech Dec. 22 at 2:56 PM
$SGMO's Fabry disease gene therapy has potential to be #once and done $FOLD GALAFOLD only addresses certain mutations. $SGMO GT has potential to address a #larger patient #population compared to #Galafold. KOL doesnt like $BMRN $FOLD galafold for severe patience
1 · Reply
biotech
biotech Dec. 22 at 2:31 PM
$SGMO $BMRN $FOLD
0 · Reply
briefingcom
briefingcom Dec. 22 at 1:46 PM
$FOLD: Amicus Therapeutics downgraded to Hold from Buy at TD Cowen; tgt $14.50 https://www.briefing.com/calendars/updown?Filter=downgrades&utm_campaign=updown&utm_medium=social&utm_source=x&utm_content=link
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:34 PM
Citigroup has updated their rating for Amicus Therapeutics ( $FOLD ) to Neutral with a price target of 14.5.
0 · Reply
Latest News on FOLD
BioMarin: Amicus Buyout Sparks My Enthusiasm

Dec 22, 2025, 3:15 PM EST - 2 days ago

BioMarin: Amicus Buyout Sparks My Enthusiasm

BMRN

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

Dec 19, 2025, 10:55 AM EST - 5 days ago

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

BMRN

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 8:13 AM EST - 5 days ago

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

BMRN

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 7:56 AM EST - 5 days ago

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

BMRN

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

Dec 19, 2025, 7:45 AM EST - 5 days ago

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BMRN

Amicus Therapeutics: Moving Towards Consistent Profitability

Nov 11, 2025, 4:56 PM EST - 6 weeks ago

Amicus Therapeutics: Moving Towards Consistent Profitability

Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 6:11 PM EST - 6 weeks ago

Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript

Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 3:56 PM EST - 7 weeks ago

Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

Nov 4, 2025, 7:00 AM EST - 7 weeks ago

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

Oct 31, 2025, 7:00 AM EDT - 7 weeks ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

Oct 23, 2025, 7:00 AM EDT - 2 months ago

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies

Oct 22, 2025, 8:47 PM EDT - 2 months ago

Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies

3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 3 months ago

3 Of My Favorite Biotech Stocks Under $10

DVAX MRNA NUVB PFE

Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 6:06 PM EDT - 3 months ago

Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Sep 8, 2025, 9:00 AM EDT - 3 months ago

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful

Aug 29, 2025, 9:06 PM EDT - 4 months ago

In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

Aug 29, 2025, 7:00 AM EDT - 4 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student

Aug 25, 2025, 4:22 PM EDT - 4 months ago

Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student

In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump

Aug 21, 2025, 6:20 PM EDT - 4 months ago

In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump

The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination

Aug 18, 2025, 2:47 PM EDT - 4 months ago

The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Aug 1, 2025, 4:04 PM EDT - 5 months ago

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 3:12 PM EDT - 5 months ago

Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

Jul 31, 2025, 7:00 AM EDT - 5 months ago

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data

Jul 28, 2025, 6:20 PM EDT - 5 months ago

In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jul 21, 2025, 7:00 AM EDT - 5 months ago

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

Jul 10, 2025, 8:00 AM EDT - 5 months ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

Jun 25, 2025, 7:00 AM EDT - 6 months ago

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

Jun 20, 2025, 5:03 PM EDT - 6 months ago

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

Jun 16, 2025, 2:02 PM EDT - 6 months ago

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

Jun 13, 2025, 6:23 PM EDT - 6 months ago

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Jun 12, 2025, 4:16 PM EDT - 6 months ago

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Jun 12, 2025, 10:14 AM EDT - 6 months ago

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Jun 3, 2025, 7:00 AM EDT - 7 months ago

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

May 30, 2025, 7:00 AM EDT - 7 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

May 7, 2025, 7:00 AM EDT - 8 months ago

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:24 PM EDT - 8 months ago

Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

May 1, 2025, 7:00 AM EDT - 8 months ago

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Apr 30, 2025, 7:12 PM EDT - 8 months ago

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

Apr 21, 2025, 7:00 AM EDT - 8 months ago

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

Mar 17, 2025, 10:21 AM EDT - 10 months ago

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer

Mar 6, 2025, 4:31 PM EST - 10 months ago

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act

Mar 3, 2025, 2:04 PM EST - 10 months ago

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

Feb 27, 2025, 7:00 AM EST - 10 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 2:04 PM EST - 11 months ago

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

Feb 19, 2025, 7:00 AM EST - 11 months ago

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm

Feb 17, 2025, 5:59 PM EST - 11 months ago

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm

JuggernautRaider
JuggernautRaider Dec. 23 at 12:59 PM
$TNXP I’ve been investing in Tonix for over a year and have noticed a lot of animus towards Seth “Leader Man”. He has done a nice job IMO since I have been invested, but he is getting up there in years. Does anyone else think he could be replaced soon like Durso did Garg at $ALT ? Any top choices? Not every CEO can be like the ones at $NUVB and $FOLD … unfortunately 😣
2 · Reply
Avocado_smash
Avocado_smash Dec. 22 at 10:35 PM
$ZIM last week $FOLD this week $ZIM 🚀🚀🚀
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 5:35 PM
$BMRN makes a bold $4.8B move — is this a rare-disease power play? 💰🧬 BioMarin agreed to acquire $FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to strengthen its portfolio. That’s immediate scale plus future optionality in one deal. Full deal breakdown and what it means for both stocks 👉 https://www.zacks.com/stock/news/2807526/biomarin-to-buy-rare-disease-drugmaker-amicus-therapeutics-for-48b?cid=sm-stocktwits-2-2807526-teaser-25832&ADID=SYND_STOCKTWITS_TWEET_2_2807526_TEASER_25832
0 · Reply
TeeMan123
TeeMan123 Dec. 22 at 5:24 PM
$FOLD well this was a long ride.. happy to see it come to fruition albeit the purchase price is much lighter than I would have expected. Signing from this board,, GL to you all going forward
0 · Reply
BullMaven
BullMaven Dec. 22 at 4:51 PM
$FOLD congrat to fold bag holders
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 4:35 PM
$BMRN makes a big move with $FOLD acquisition! 💥 BioMarin is acquiring Amicus Therapeutics for $4.8B, boosting its rare disease portfolio with Galafold and Pombiliti-Opfolda. This strategic deal, expected to close in Q2 2026, is expected to be accretive within the first 12 months post-closure. 📈 Discover how this deal could reshape BMRN's future here 👉 https://www.zacks.com/stock/news/2807526/biomarin-to-buy-rare-disease-drugmaker-amicus-therapeutics-for-48b?cid=sm-stocktwits-2-2807526-body-25834&ADID=SYND_STOCKTWITS_TWEET_2_2807526_BODY_25834
0 · Reply
biotech
biotech Dec. 22 at 2:56 PM
$SGMO's Fabry disease gene therapy has potential to be #once and done $FOLD GALAFOLD only addresses certain mutations. $SGMO GT has potential to address a #larger patient #population compared to #Galafold. KOL doesnt like $BMRN $FOLD galafold for severe patience
1 · Reply
biotech
biotech Dec. 22 at 2:31 PM
$SGMO $BMRN $FOLD
0 · Reply
briefingcom
briefingcom Dec. 22 at 1:46 PM
$FOLD: Amicus Therapeutics downgraded to Hold from Buy at TD Cowen; tgt $14.50 https://www.briefing.com/calendars/updown?Filter=downgrades&utm_campaign=updown&utm_medium=social&utm_source=x&utm_content=link
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:34 PM
Citigroup has updated their rating for Amicus Therapeutics ( $FOLD ) to Neutral with a price target of 14.5.
0 · Reply
tradeitbetit
tradeitbetit Dec. 22 at 2:32 AM
$BMRN $FOLD $SGMO wow what an acquisition
1 · Reply
biotech
biotech Dec. 21 at 5:09 PM
$SGMO Jefferies: $BMRN $FOLD Galafold for Fabry's pts with amenable GLA mutations (~35-50% of Fabry pts) potentially >100k undiagnosed Jefferies says "the most #material near-term #competitor is $SGMO Sangamo's ST-920, which is an AAV gene tx w/ BLA under AA expected Q2'26 based on Ph.1/2 data"
1 · Reply
JFais
JFais Dec. 21 at 1:47 PM
Houbi on $BMRN post $FOLD acquisition
0 · Reply
RichRich48
RichRich48 Dec. 21 at 2:47 AM
$FOLD Fold be the next Boom? Asking for a friend?
0 · Reply
Djmoonstone
Djmoonstone Dec. 20 at 3:22 AM
$MNKD Amicus $FOLD just sold for over $14 a share. They have negative net cash, compared to $MNKD $34.6 million and $9.7 million free cash flow compared to $MNKD $43.4 million. This company is set up with a foundation stronger than ever and is currently improperly valued. Watch.
0 · Reply
FRAGMENTS
FRAGMENTS Dec. 20 at 12:09 AM
$FOLD $TSLA $AAPL $T
0 · Reply
RunnerSignals
RunnerSignals Dec. 19 at 10:06 PM
$FOLD didn't rally because hope got louder it rallied because uncertainty got removed https://stocksrunner.com/news/2025-12-19-bull-of-the-day
0 · Reply
TheRoaringBunny
TheRoaringBunny Dec. 19 at 10:05 PM
$FLGC $FOLD $JLHL $LUNR $MU $FLGC is now ZERO STACK with $100M of crypto against a $6M market cap SHUT THE FRONT DOOR FLGC $7.50 to $100? Pre approved Approved FORWARD SPLIT? Why do we need this? MOON NOW? CYPH / SMX time baby!
1 · Reply
Few_erish
Few_erish Dec. 19 at 8:33 PM
$FOLD M&A sympathy, insane liquidity
0 · Reply
JFais
JFais Dec. 19 at 8:28 PM
Days like today our Real-Time Trades channel shines Ppl moving $FOLD profits into new setups according to their own selection criteria (if nothing else, helps with idea generation) Was discussing w/ @WassimLaroussi3 - bouncing ideas off others helps with avoiding the landmines
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 19 at 8:09 PM
$FOLD Massive volume spike on Dec 19, 2025, with 159,889,379 shares traded, way above the 4,823,930 average volume. Price held at $14.20. Huge price jump from the low of $5.64. Smart move might be to wait for H% to cool down before considering an entry.
0 · Reply
topstockalerts
topstockalerts Dec. 19 at 7:52 PM
Top Gainers PT2 $LUNR $RKLX $BENF $AFJKU $FOLD
0 · Reply